VTYX

Ventyx Biosciences (VTYX)

About Ventyx Biosciences (VTYX)

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Details

Daily high

$7.86

Daily low

$7.59

Price at open

$7.76

52 Week High

$10.55

52 Week Low

$0.78

Market cap

548.7M

Dividend yield

0.00%

Volume

784,812

Avg. volume

1.8M

P/E ratio

-5.13

Ventyx Biosciences News